Inflammation, oxidative stress, and procoagulant and thrombotic activity in adults with obstructive sleep apnea

Advances in Cardiology

Volumn 46, Issue , 2011, Pages 43-66

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTANE; C REACTIVE PROTEIN; CHEMOKINE; CYTOKINE; HOMOCYSTEINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 8; LEUKOTRIENE; MEMBRANE PROTEIN; NITRIC OXIDE; PEROXIDE; PEROXYNITRITE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P50; PROTEIN P52; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RECEPTOR PROTEIN; SUPEROXIDE; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTOR ALPHA; URIC ACID;

ADULT DISEASE; AIRWAY PRESSURE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DNA FRAGMENTATION; ENDOTHELIAL DYSFUNCTION; HOMEOSTASIS; HUMAN; HYPERCOAGULABILITY; HYPOXIA; INFLAMMATION; INTERVENTION STUDY; LIPID PEROXIDATION; LONGITUDINAL STUDY; METABOLIC DISORDER; NITROSATIVE STRESS; OXIDATIVE STRESS; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; SLEEP APNEA SYNDROME; THROMBOSIS; URIC ACID URINE LEVEL;

ADULT; BLOOD COAGULATION DISORDERS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; METABOLIC DISEASES; OXIDATIVE STRESS; SLEEP APNEA, OBSTRUCTIVE; TRANSCRIPTION FACTORS;

EID: 82755195283     PISSN: 00652326     EISSN: 16622839     Source Type: Book Series    
DOI: 10.1159/000325105     Document Type: Article

References (121)

1. Arnardottir ES, Mackiewicz M, Gislason T, Teff KL, Pack AI: Molecular signatures of obstructive sleep apnea in adults: a review and perspective. Sleep 2009;32:447-470.
2. Lavie L, Lavie P: Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link. Eur Respir J 2009;33:1467-1484.
3. Spiegel K, Tasali E, Leproult R, Van Cauter E: Effects of poor and short sleep on glucose metabolism and obesity risk. Nat Rev Endocrinol 2009;5:253-261.
4. Ye J: Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int J Obes (Lond) 2009;33:54-66.
5. Garvey JF, Taylor CT, McNicholas WT: Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation. Eur Respir J 2009;33:1195-1205.
6. Nanduri J, Yuan G, Kumar GK, Semenza GL, Prabhakar NR: Transcriptional responses to intermittent hypoxia. Respir Physiol Neurobiol 2008;164: 277-281.
7. Ryan S, Taylor CT, McNicholas WT: Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005;112:2660-2667. (Pubitemid 41532603)
8. Ryan S, McNicholas WT, Taylor CT: A critical role for p38 map kinase in NF- kappaB signaling during intermittent hypoxia/reoxygenation. Biochem Biophys Res Commun 2007;355:728-733. (Pubitemid 46330212)
9. 2+/calmodulin kinase- dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. J Biol Chem 2005;280:4321-4328. (Pubitemid 40288600)
10. 2+ signaling, prolyl hydroxylases, and mTOR. J Cell Physiol 2008;217:674-685.
11. Lam SY, Tipoe GL, Liong EC, Fung ML: Differential expressions and roles of hypoxia- inducible factor- 1alpha, - 2alpha and - 3alpha in the rat carotid body during chronic and intermittent hypoxia. Histol Histopathol 2008;23:271-280.
12. Nanduri J, Wang N, Yuan G, Khan SA, Souvannakitti D, Peng YJ, Kumar GK, Garcia JA, Prabhakar NR: Intermittent hypoxia degrades HIF- 2alpha via calpains resulting in oxidative stress: implications for recurrent apnea- induced morbidities. Proc Natl Acad Sci USA 2009;106:1199-1204.
13. Monaco C, Paleolog E: Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res 2004;61:671-682. (Pubitemid 38249466)
14. Shoelson SE, Lee J, Goldfine AB: Inflammation and insulin resistance. J Clin Invest 2006;116:1793-1801. (Pubitemid 44033299)
15. Greenberg H, Ye X, Wilson D, Htoo AK, Hendersen T, Liu SF: Chronic intermittent hypoxia activates nuclear factor- kappaB in cardiovascular tissues in vivo. Biochem Biophys Res Commun 2006;343: 591-596.
16. Htoo AK, Greenberg H, Tongia S, Chen G, Henderson T, Wilson D, Liu SF: Activation of nuclear factor kappaB in obstructive sleep apnea: a pathway leading to systemic inflammation. Sleep Breath 2006;10:43-50. (Pubitemid 44193436)
17. Jelic S, Lederer DJ, Adams T, Padeletti M, Colombo PC, Factor PH, Le Jemtel TH: Vascular inflammation in obesity and sleep apnea. Circulation 2010; 121:1014-1021.
18. Ryan S, Taylor CT, McNicholas WT: Predictors of elevated nuclear factor- kappaB- dependent genes in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2006;174:824-830. (Pubitemid 44511665)
19. Sahlman J, Miettinen K, Peuhkurinen K, Seppa J, Peltonen M, Herder C, Punnonen K, Vanninen E, Gylling H, Partinen M, Uusitupa M, Tuomilehto H: The activation of the inflammatory cytokines in overweight patients with mild obstructive sleep apnoea. J Sleep Res 2010;19:341-348.
20. Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G, Hirano T, Adachi M: Elevated levels of C- reactive protein and interleukin- 6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003;107:1129-1134. (Pubitemid 36297204)
21. Kim J, Lee CH, Park CS, Kim BG, Kim SW, Cho JH: Plasma levels of MCP- 1 and adiponectin in obstructive sleep apnea syndrome. Arch Otolaryngol Head Neck Surg 2010;136:896-899.
22. Ohga E, Nagase T, Tomita T, Teramoto S, Matsuse T, Katayama H, Ouchi Y: Increased levels of circulating ICAM- 1, VCAM- 1 and L- selectin in obstructive sleep apnea syndrome. J Appl Physiol 1999;87:10-14. (Pubitemid 29330658)
23. Riha RL, Brander P, Vennelle M, McArdle N, Kerr SM, Anderson NH, Douglas NJ: Tumour necrosis factor- alpha (- 308) gene polymorphism in obstructive sleep apnoea- hypopnoea syndrome. Eur Respir J 2005;26:673-678. (Pubitemid 41448667)
24. Bhushan B, Guleria R, Misra A, Luthra K, Vikram NK: TNF- alpha gene polymorphism and TNFalpha levels in obese Asian Indians with obstructive sleep apnea. Respir Med 2009;103:386-392.
25. Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J, Gleadle JM: Concordant regulation of gene expression by hypoxia and 2- oxoglutaratedependent dioxygenase inhibition: the role of HIF- 1alpha, HIF- 2alpha, and other pathways. J Biol Chem 2006;281:15215-15226. (Pubitemid 43855111)
26. Lavie L, Kraiczi H, Hefetz A, Ghandour H, Perelman A, Hedner J, Lavie P: Plasma vascular endothelial growth factor in sleep apnea syndrome: effects of nasal continuous positive air pressure treatment. Am J Respir Crit Care Med 2002;165:1624-1628. (Pubitemid 34693942)
27. Garcia de la Torre N, Rubio MA, Bordiu E, Cabrerizo L, Aparicio E, Hernandez C, Sanchez- Pernaute A, Diez- Valladares L, Torres AJ, Puente M, Charro AL: Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor- A, adipocytokines, and insulin. J Clin Endocrinol Metab 2008;93:4276-4281. (Pubitemid 352789522)
28. Valipour A, Litschauer B, Mittermayer F, Rauscher H, Burghuber OC, Wolzt M: Circulating plasma levels of vascular endothelial growth factor in patients with sleep disordered breathing. Respir Med 2004;98:1180-1186. (Pubitemid 39497219)
29. De la Pena M, Barcelo A, Barbe F, Pierola J, Pons J, Rimbau E, Ayllon O, Agusti AG: Endothelial function and circulating endothelial progenitor cells in patients with sleep apnea syndrome. Respiration 2008;76:28-32. (Pubitemid 351914136)
30. Takahashi S, Nakamura Y, Nishijima T, Sakurai S, Inoue H: Essential roles of angiotensin II in vascular endothelial growth factor expression in sleep apnea syndrome. Respir Med 2005;99:1125-1131. (Pubitemid 41102649)
31. Winnicki M, Shamsuzzaman A, Lanfranchi P, Accurso V, Olson E, Davison D, Somers VK: Erythropoietin and obstructive sleep apnea. Am J Hypertens 2004;17:783-786. (Pubitemid 39201093)
32. Lavie L: Oxidative stress - a unifying paradigm in obstructive sleep apnea and comorbidities. Prog Cardiovasc Dis 2009;51:303-312.
33. Pialoux V, Hanly PJ, Foster GE, Brugniaux JV, Beaudin AE, Hartmann SE, Pun M, Duggan CT, Poulin MJ: Effects of exposure to intermittent hypoxia on oxidative stress and acute hypoxic ventilator response in humans. Am J Respir Crit Care Med 2009;180:1002-1009.
34. Stocker R, Keaney JF Jr: Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84:1381-1478. (Pubitemid 39302636)
35. Griendling KK, FitzGerald GA: Oxidative stress and cardiovascular injury. I. Basic mechanisms and in vivo monitoring of ROS. Circulation 2003;108:1912-1916. (Pubitemid 37296532)
36. Seddon M, Looi YH, Shah AM: Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 2007;93:903-907. (Pubitemid 47122034)
37. Gaston B, Singel D, Doctor A, Stamler JS: S- nitrosothiol signaling in respiratory biology. Am J Respir Crit Care Med 2006;173:1186-1193.
38. Manukhina EB, Downey HF, Mallet RT: Role of nitric oxide in cardiovascular adaptation to intermittent hypoxia. Exp Biol Med (Maywood) 2006;231:343-365.
39. Gozal D, Kheirandish- Gozal L: Cardiovascular morbidity in obstructive sleep apnea: oxidative stress, inflammation, and much more. Am J Respir Crit Care Med 2008;177:369-375. (Pubitemid 351317579)
40. Thum T, Fraccarollo D, Thum S, Schultheiss M, Daiber A, Wenzel P, Munzel T, Ertl G, Bauersachs J: Differential effects of organic nitrates on endo thelial progenitor cells are determined by oxidative stress. Arterioscler Thromb Vasc Biol 2007;27:748-754. (Pubitemid 46606702)
41. Dyugovskaya L, Lavie P, Lavie L: Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 2002; 165:934-939. (Pubitemid 34774660)
42. Schulz R, Mahmoudi S, Hattar K, Sibelius U, Olschewski H, Mayer K, Seeger W, Grimminger F: Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea: impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med 2000;162:566-570. (Pubitemid 30647201)
43. Lavie L: Obstructive sleep apnoea syndrome - an oxidative stress disorder. Sleep Med Rev 2003;7: 35-51. (Pubitemid 36188305)
44. Alonso- Fernandez A, Garcia- Rio F, Arias MA, Hernanz A, de la Pena M, Pierola J, Barcelo A, Lopez- Collazo E, Agusti A: Effects of CPAP on oxidative stress and nitrate efficiency in sleep apnoea: a randomised trial. Thorax 2009;64:581-586.
45. Minoguchi K, Yokoe T, Tanaka A, Ohta S, Hirano T, Yoshino G, O'Donnell CP, Adachi M: Association between lipid peroxidation and inflammation in obstructive sleep apnoea. Eur Respir J 2006;28: 378-385. (Pubitemid 44914239)
46. Carpagnano GE, Kharitonov SA, Resta O, Foschino- Barbaro MP, Gramiccioni E, Barnes PJ: Increased 8- isoprostane and interleukin- 6 in breath condensate of obstructive sleep apnea patients. Chest 2002; 122:1162-1167. (Pubitemid 35339525)
47. Carpagnano GE, Kharitonov SA, Resta O, Foschino- Barbaro MP, Gramiccioni E, Barnes PJ: 8- Isoprostane, a marker of oxidative stress, is increased in exhaled breath condensate of patients with obstructive sleep apnea after night and is reduced by continuous positive airway pressure therapy. Chest 2003;124:1386-1392. (Pubitemid 37290049)
48. Barcelo A, Miralles C, Barbe F, Vila M, Pons S, Agusti AG: Abnormal lipid peroxidation in patients with sleep apnoea. Eur Respir J 2000;16:644-647.
49. Lavie L, Vishnevsky A, Lavie P: Evidence for lipid peroxidation in obstructive sleep apnea. Sleep 2004; 27:123-128. (Pubitemid 43906323)
50. Kizawa T, Nakamura Y, Takahashi S, Sakurai S, Yamauchi K, Inoue H: Pathogenic role of angiotensin II and oxidised LDL in obstructive sleep apnoea. Eur Respir J 2009;34:1390-1398.
51. Jurado- Gamez B, Fernandez- Marin MC, Gomez- Chaparro JL, Munoz- Cabrera L, Lopez- Barea J, Perez- Jimenez F, Lopez- Miranda J: Relationship of oxidative stress and endothelial dysfunction in sleep apnoea. Eur Respir J 2011;37:873-879.
52. Jelic S, Padeletti M, Kawut SM, Higgins C, Canfield SM, Onat D, Colombo PC, Basner RC, Factor P, LeJemtel TH: Inflammation, oxidative stress, and repair capacity of the vascular endothelium in obstructive sleep apnea. Circulation 2008;117: 2270-2278.
53. Patt BT, Jarjoura D, Haddad DN, Sen CK, Roy S, Flavahan NA, Khayat RN: Endothelial dysfunction in the microcirculation of patients with obstructive sleep apnea. Am J Respir Crit Care Med 2010;182: 1540-1545.
54. Yamauchi M, Nakano H, Maekawa J, Okamoto Y, Ohnishi Y, Suzuki T, Kimura H: Oxidative stress in obstructive sleep apnea. Chest 2005;127:1674-1679. (Pubitemid 46218794)
55. Sahebjani H: Changes in urinary uric acid excretion in obstructive sleep apnea before and after therapy with nasal continuous positive airway pressure. Chest 1998;113:1604-1608.
56. Lavie L, Perelman A, Lavie P: Plasma homocysteine levels in obstructive sleep apnea: association with cardiovascular morbidity. Chest 2001;120:900- 908. (Pubitemid 32885467)
57. Can M, Acikgoz S, Mungan G, Bayraktaroglu T, Kocak E, Guven B, Demirtas S: Serum cardiovascular risk factors in obstructive sleep apnea. Chest 2006;129:233-237. (Pubitemid 43289839)
58. Jordan W, Berger C, Cohrs S, Rodenbeck A, Mayer G, Niedmann PD, von Ahsen N, Ruther E, Kornhuber J, Bleich S: CPAP- therapy effectively lowers serum homocysteine in obstructive sleep apnea syndrome. J Neural Transm 2004;111: 683-689. (Pubitemid 38716548)
59. Christou K, Moulas AN, Pastaka C, Gourgoulianis KI: Antioxidant capacity in obstructive sleep apnea patients. Sleep Med 2003;4:225-228. (Pubitemid 36748608)
60. Barcelo A, Barbe F, de la Pena M, Vila M, Perez G, Pierola J, Duran J, Agusti AG: Antioxidant status in patients with sleep apnoea and impact of continuous positive airway pressure treatment. Eur Respir J 2006;27:756-760. (Pubitemid 44914199)
61. Faure P, Tamisier R, Baguet JP, Favier A, Halimi S, Levy P, Pepin JL: Impairment of serum albumin antioxidant properties in obstructive sleep apnoea syndrome. Eur Respir J 2008;31:1046-1053.
62. Grebe M, Eisele HJ, Weissmann N, Schaefer C, Tillmanns H, Seeger W, Schulz R: Antioxidant vitamin C improves endothelial function in obstructive sleep apnea. Am J Respir Crit Care Med 2006;173: 897-901.
63. El Solh AA, Saliba R, Bosinski T, Grant BJ, Berbary E, Miller N: Allopurinol improves endothelial function in sleep apnoea: a randomised controlled study. Eur Respir J 2006;27:997-1002. (Pubitemid 44911115)
64. Svatikova A, Wolk R, Lerman LO, Juncos LA, Greene EL, McConnell JP, Somers VK: Oxidative stress in obstructive sleep apnoea. Eur Heart J 2005; 26:2435-2439. (Pubitemid 41552973)
65. Alzoghaibi MA, Bahammam AS: Lipid peroxides, superoxide dismutase and circulating IL- 8 and GCP- 2 in patients with severe obstructive sleep apnea: a pilot study. Sleep Breath 2005;9:119-126. (Pubitemid 44193442)
66. Svatikova A, Wolk R, Wang HH, Otto ME, Bybee KA, Singh RJ, Somers VK: Circulating free nitrotyrosine in obstructive sleep apnea. Am J Physiol Regul Integr Comp Physiol 2004;287:R284-R287. (Pubitemid 38970278)
67. Svatikova A, Wolk R, Magera MJ, Shamsuzzaman AS, Phillips BG, Somers VK: Plasma homocysteine in obstructive sleep apnoea. Eur Heart J 2004;25: 1325-1329. (Pubitemid 38998509)
68. Ryan S, Nolan GM, Hannigan E, Cunningham S, Taylor C, McNicholas WT: Cardiovascular risk markers in obstructive sleep apnoea syndrome and correlation with obesity. Thorax 2007;62:509-514. (Pubitemid 46910129)
69. Mullington JM, Haack M, Toth M, Serrador JM, Meier- Ewert HK: Cardiovascular, inflammatory, and metabolic consequences of sleep deprivation. Prog Cardiovasc Dis 2009;51:294-302.
70. Van Leeuwen WM, Lehto M, Karisola P, Lindholm H, Luukkonen R, Sallinen M, Harma M, Porkka- Heiskanen T, Alenius H: Sleep restriction increases the risk of developing cardiovascular diseases by augmenting proinflammatory responses through IL- 17 and CRP. PLoS One 2009;4:e4589.
71. Sauvet F, Leftheriotis G, Gomez- Merino D, Langrume C, Drogou C, Van Beers P, Bourrilhon C, Florence G, Chennaoui M: Effect of acute sleep deprivation on vascular function in healthy subjects. J Appl Physiol 2010;108:68-75.
72. Meier- Ewert HK, Ridker PM, Rifai N, Regan MM, Price NJ, Dinges DF, Mullington JM: Effect of sleep loss on C- reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol 2004;43: 678-683. (Pubitemid 38229544)
73. Taheri S, Austin D, Lin L, Nieto FJ, Young T, Mignot E: Correlates of serum C- reactive protein (CRP) - no association with sleep duration or sleep disordered breathing. Sleep 2007;30:991-996. (Pubitemid 47221899)
74. Croce K, Libby P: Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 2007;14:55-61. (Pubitemid 44885613)
75. Von Kanel R, Loredo JS, Ancoli- Israel S, Mills PJ, Dimsdale JE: Elevated plasminogen activator inhibitor 1 in sleep apnea and its relation to the metabolic syndrome: an investigation in 2 different study samples. Metabolism 2007;56:969-976. (Pubitemid 46900834)
76. Zamarron C, Ricoy J, Riveiro A, Gude F: Plasminogen activator inhibitor- 1 in obstructive sleep apnea patients with and without hypertension. Lung 2008;186:151-156.
77. Von Kanel R, Loredo JS, Ancoli- Israel S, Dimsdale JE: Association between sleep apnea severity and blood coagulability: treatment effects of nasal continuous positive airway pressure. Sleep Breath 2006; 10:139-146. (Pubitemid 44322495)
78. Rangemark C, Hedner JA, Carlson JT, Gleerup G, Winther K: Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients. Sleep 1995;18:188-194.
79. Mehra R, Xu F, Babineau DC, Tracy RP, Jenny NS, Patel SR, Redline S: Sleep- disordered breathing and prothrombotic biomarkers: cross- sectional results of the Cleveland Family Study. Am J Respir Crit Care Med 2010;182:826-833.
80. Saletu M, Nosiska D, Kapfhammer G, Lalouschek W, Saletu B, Benesch T, Zeitlhofer J: Structural and serum surrogate markers of cerebrovascular disease in obstructive sleep apnea (OSA): association of mild OSA with early atherosclerosis. J Neurol 2006; 253:746-752. (Pubitemid 43980146)
81. Steiner S, Jax T, Evers S, Hennersdorf M, Schwalen A, Strauer BE: Altered blood rheology in obstructive sleep apnea as a mediator of cardiovascular risk. Cardiology 2005;104:92-96. (Pubitemid 41197018)
82. Chin K, Ohi M, Kita H, Noguchi T, Otsuka N, Tsuboi T, Mishima M, Kuno K: Effects of NCPAP therapy on fibrinogen levels in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 1996;153:1972-1976. (Pubitemid 26187928)
83. Robinson GV, Pepperell JC, Segal HC, Davies RJ, Stradling JR: Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomized controlled trials. Thorax 2004;59:777-782. (Pubitemid 39215375)
84. Akinnusi ME, Paasch LL, Szarpa KR, Wallace PK, El Solh AA: Impact of nasal continuous positive airway pressure therapy on markers of platelet activation in patients with obstructive sleep apnea. Respiration 2009;77:25-31.
85. Oga T, Chin K, Tabuchi A, Kawato M, Morimoto T, Takahashi K, Handa T, Taniguchi R, Kondo H, Mishima M, Kita T, Horiuchi H: Effects of obstructive sleep apnea with intermittent hypoxia on platelet aggregability. J Atheroscler Thromb 2009;16: 862-869.
86. O'Brien LM, Serpero LD, Tauman R, Gozal D: Plasma adhesion molecules in children with sleepdisordered breathing. Chest 2006;129:947- 953.
87. Chin K, Kita H, Noguchi T, Otsuka N, Tsuboi T, Nakamura T, Shimizu K, Mishima M, Ohi M: Improvement of factor VII clotting activity following long- term NCPAP treatment in obstructive sleep apnoea syndrome. Q J Med 1998;91:627-633. (Pubitemid 28438236)
88. Shitrit D, Peled N, Shitrit AB, Meidan S, Bendayan D, Sahar G, Kramer MR: An association between oxygen desaturation and D- dimer in patients with obstructive sleep apnea syndrome. Thromb Haemost 2005;94:544-547. (Pubitemid 41300850)
89. Von Kanel R, Loredo JS, Ancoli- Israel S, Mills PJ, Natarajan L, Dimsdale JE: Association between polysomnographic measures of disrupted sleep and prothrombotic factors. Chest 2007;131:733-739. (Pubitemid 46446864)
90. Von Kanel R, Natarajan L, Ancoli- Israel S, Mills PJ, Loredo JS, Dimsdale JE: Day/night rhythm of hemostatic factors in obstructive sleep apnea. Sleep 2010;33:371-377.
91. Quan SF, Gersh BJ: Cardiovascular consequences of sleep- disordered breathing: past, present and future: report of a workshop from the National Center on Sleep Disorders Research and the National Heart, Lung, and Blood Institute. Circulation 2004;109:951-957. (Pubitemid 38282845)
92. Mausbach BT, Ancoli- Israel S, von Kanel R, Patterson TL, Aschbacher K, Mills PJ, Ziegler MG, Dimsdale JE, Calleran S, Grant I: Sleep disturbance, norepinephrine, and D- dimer are all related in elderly caregivers of people with Alzheimer disease. Sleep 2006;29:1347-1352. (Pubitemid 44571989)
93. Von Kanel R, Dimsdale JE, Ancoli- Israel S, Mills PJ, Patterson TL, McKibbin CL, Archuleta C, Grant I: Poor sleep is associated with higher plasma proinflammatory cytokine interleukin- 6 and procoagulant marker fibrin D- dimer in older caregivers of people with Alzheimer's disease. J Am Geriatr Soc 2006;54:431-437. (Pubitemid 43327154)
94. Gonzalez- Periz A, Claria J: Resolution of adipose tissue inflammation. Sci World J 2010;10:832-856.
95. Stanke- Labesque F, Back M, Lefebvre B, Tamisier R, Baguet JP, Arnol N, Levy P, Pepin JL: Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia. J Allergy Clin Immunol 2009;124:364-370.
96. Dyugovskaya L, Lavie P, Lavie L: Phenotypic and functional characterization of blood gammadelta T cells in sleep apnea. Am J Respir Crit Care Med 2003;168:242-249. (Pubitemid 36920981)
97. Dyugovskaya L, Lavie P, Hirsh M, Lavie L: Activated CD8+ T- lymphocytes in obstructive sleep apnoea. Eur Respir J 2005;25:820-828. (Pubitemid 40667679)
98. Riccioni G, Back M, Capra V: Leukotrienes and atherosclerosis. Curr Drug Targets 2010;11:882-887.
99. Goldbart AD, Goldman JL, Li RC, Brittian KR, Tauman R, Gozal D: Differential expression of cysteinyl leukotriene receptors 1 and 2 in tonsils of children with obstructive sleep apnea syndrome or recurrent infection. Chest 2004;126:13-18. (Pubitemid 38943111)
100. Goldbart AD, Goldman JL, Veling MC, Gozal D: Leukotriene modifier therapy for mild sleepdisordered breathing in children. Am J Respir Crit Care Med 2005;172:364-370. (Pubitemid 41026148)
101. Goldbart AD, Krishna J, Li RC, Serpero LD, Gozal D: Inflammatory mediators in exhaled breath condensate of children with obstructive sleep apnea syndrome. Chest 2006;130:143-148. (Pubitemid 44116852)
102. Kheirandish L, Goldbart AD, Gozal D: Intranasal steroids and oral leukotriene modifier therapy in residual sleep- disordered breathing after tonsillectomy and adenoidectomy in children. Pediatrics 2006;117:e61-e66. (Pubitemid 46061089)
103. Berlucchi M, Salsi D, Valetti L, Parrinello G, Nicolai P: The role of mometasone furoate aqueous nasal spray in the treatment of adenoidal hypertrophy in the pediatric age group: preliminary results of a prospective, randomized study. Pediatrics 2007;119: e1392-e1397. (Pubitemid 46871326)
104. Kaditis AG, Ioannou MG, Chaidas K, Alexopoulos EI, Apostolidou M, Apostolidis T, Koukoulis G, Gourgoulianis K: Cysteinyl leukotriene receptors are expressed by tonsillar T cells of children with obstructive sleep apnea. Chest 2008;134:324-331.
105. Kaditis AG, Alexopoulos E, Chaidas K, Ntamagka G, Karathanasi A, Tsilioni I, Kiropoulos TS, Zintzaras E, Gourgoulianis K: Urine concentrations of cysteinyl leukotrienes in children with obstructive sleep- disordered breathing. Chest 2009;135: 1496-1501.
106. Lefebvre B, Pepin JL, Baguet JP, Tamisier R, Roustit M, Riedweg K, Bessard G, Levy P, Stanke- Labesque F: Leukotriene B4: early mediator of atherosclerosis in obstructive sleep apnoea? Eur Respir J 2008;32: 113-120.
107. Petrosyan M, Perraki E, Simoes D, Koutsourelakis I, Vagiakis E, Roussos C, Gratziou C: Exhaled breath markers in patients with obstructive sleep apnoea. Sleep Breath 2008;12:207-215.
108. Blake GJ, Ridker PM: C- reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003;41:37S- 42S.
109. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: C- reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350: 1387-1397. (Pubitemid 38419992)
110. Khera A, de Lemos JA, Peshock RM, Lo HS, Stanek HG, Murphy SA, Wians FH Jr, Grundy SM, McGuire DK: Relationship between C- reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation 2006;113:38-43. (Pubitemid 43958486)
111. Lui MM, Lam JC, Mak HK, Xu A, Ooi C, Lam DC, Mak JC, Khong PL, Ip MS: C- reactive protein is associated with obstructive sleep apnea independent of visceral obesity. Chest 2009;135:950-956.
112. Akashiba T, Akahoshi T, Kawahara S, Majima T, Horie T: Effects of long- term nasal continuous positive airway pressure on C- reactive protein in patients with obstructive sleep apnea syndrome. Intern Med 2005;44:899-900. (Pubitemid 41263844)
113. Sharma SK, Mishra HK, Sharma H, Goel A, Sreenivas V, Gulati V, Tahir M: Obesity, and not obstructive sleep apnea, is responsible for increased serum hs- CRP levels in patients with sleepdisordered breathing in Delhi. Sleep Med 2008;9: 149-156.
114. Phillips CL, Yang Q, Williams A, Roth M, Yee BJ, Hedner JA, Berend N, Grunstein RR: The effect of short- term withdrawal from continuous positive airway pressure therapy on sympathetic activity and markers of vascular inflammation in subjects with obstructive sleep apnoea. J Sleep Res 2007;16: 217-225. (Pubitemid 46850092)
115. Atkeson A, Yeh SY, Malhotra A, Jelic S: Endothelial function in obstructive sleep apnea. Prog Cardiovasc Dis 2009;51:351-362.
116. Kohler M, Ayers L, Pepperell JC, Packwood KL, Ferry B, Crosthwaite N, Craig S, Siccoli MM, Davies RJ, Stradling JR: Effects of continuous positive airway pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnoea: a randomised controlled trial. Thorax 2009;64:67-73.
117. Bradley TD, Floras JS: Obstructive sleep apnoea and its cardiovascular consequences. Lancet 2009;373: 82-93.
118. Dematteis M, Godin- Ribuot D, Arnaud C, Ribuot C, Stanke- Labesque F, Pepin JL, Levy P: Cardiovascular consequences of sleep- disordered breathing: contribution of animal models to understanding the human disease. ILAR J 2009;50: 262-281.
119. Jun J, Polotsky VY: Metabolic consequences of sleepdisordered breathing. ILAR J 2009;50: 289-306.
120. Kanagy NL: Vascular effects of intermittent hypoxia. ILAR J 2009;50:282-288.
121. Ayers L, Ferry B, Craig S, Nicoll D, Stradling JR, Kohler M: Circulating cell- derived microparticles in patients with minimally symptomatic obstructive sleep apnoea. Eur Respir J 2009;33:574-580.